Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva/Ranbaxy launch Accupril generic

Executive Summary

Teva/Ranbaxy launch first generic version of Pfizer's Accupril (quinapril) Dec. 15 following FDA approval of Ranbaxy's ANDA. The generic is being manufactured by Ranbaxy, with Teva handling distribution and marketing pursuant to an exclusive supply agreement between the companies. Teva relinquished its 180-day exclusivity, allowing FDA to approve Ranbaxy's ANDA; five other companies hold tentative ANDA approval. Court rulings finding Teva's ANDA infringed a valid Pfizer patent prevented Teva from bringing its own generic to market (1"The Pink Sheet" July 5, 2004, p. 11)...

You may also be interested in...

Pfizer sues over Accupril generic

Newark, N.J. federal judge will hear arguments March 15 on Pfizer's request to preliminarily enjoin Teva and Ranbaxy from infringing an Accupril patent. Pfizer filed suit Jan. 28, alleging that the companies' generic quinapril infringes the patent. A court previously ruled that Teva's ANDA infringed, but Pfizer had not previously sued Ranbaxy. Teva began shipping quinapril manufactured under Ranbaxy's ANDA on Dec. 15 after Teva relinquished 180-day generic exclusivity rights (1"The Pink Sheet" Dec. 20, 2004, In Brief)...

Pfizer Accupril Patent Victory Could Lead To Influx Of Generics In 2005

Accupril generics could enter the market as early as 2005 despite a court ruling finding a Pfizer quinapril patent to be valid

Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?

Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from Bill Gates, it has a chance to prove the doubters wrong




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts